Senolytics · dosing
Senolytic dosage: mouse arithmetic and a handful of patients
No senolytic dosage has been validated in people: the first human pilot dosed for just 3 days (per Hickson 2019). The hit-and-run protocols online are body-weight conversions from rodent experiments, or copies of pilots that used a cancer drug rather than the supplement you are holding.
Why is senolytic dosing intermittent?
Because every senolytic dosage schedule assumes the cells return slowly, a burst as short as 3 days (per Hickson 2019) should clear them for months. Senescent cells accumulate slowly and do not divide, so once they are killed there is no need to keep killing them.[1]
A short burst of dosing followed by a long gap should, in principle, clear the population and let months pass before it rebuilds. That logic gave the field its hit-and-run design, carried into the human pilots and into every consumer protocol since.
A rationale, not a finding
Nobody has compared intermittent against continuous dosing in people. The gap length in any schedule you read is a convention, chosen because it sounds proportionate to how slowly the cells return.
What doses were used in human senolytic trials?
Limited evidence Dasatinib with quercetin, for 3 days in the first report and for 6 months in a later pilot. The combination people copy was first worked out in aged mice, where dasatinib with quercetin improved physical function and extended remaining lifespan.[2]
The first human report gave the same pair to 9 patients with diabetic kidney disease for 3 days and found fewer senescent cells in fat tissue afterward (per Hickson 2019).[3]
Show the numbers as a table
| Measure | Value |
|---|---|
| Hickson 2019 pilot | 3 days |
| Lee 2024 pilot | 6 months |
Both pilots used dasatinib, a prescription tyrosine kinase inhibitor with real toxicity, doing much of the pharmacological work. A later pilot ran the pairing for far longer and tracked DNA methylation clocks rather than tissue.[4]
What that evidence adds up to
So the human dosing evidence is a prescription drug given to small groups and measured against markers.
When the markers moved the wrong way
The longest pilot is the one enthusiasts cite least. Across 19 people taking the dasatinib and quercetin stack for 6 months (per Lee 2024), the Hannum clock read older rather than younger at 3 and 6 months, the two Horvath clocks read older at 3 months, and telomere length fell; GrimAge and DunedinPACE showed no change.
That is not proof of harm, but it removes the idea that a senolytic dosage schedule reliably rejuvenates. If the flagship stack can push some aging markers in the wrong direction, self-dosing on the promise of a younger biological age rests on nothing measured.
- What this does not say
- Uncontrolled pilot; epigenetic clock changes may not reflect clinical harm, and clock choice changed the conclusion. The paper's Table 2 also shows DNAm PhenoAge higher at 3 and 6 months, although its abstract groups the second-generation clocks as unchanged.
Where do the fisetin doses online come from?
From mouse arithmetic, not from any of that. Every fisetin senolytic protocol traces to the 2018 screen that ranked the compound most potent among 10 flavonoids (per Yousefzadeh 2018), with intermittent dosing in progeroid and aged mice.[5] Convert the rodent dose by body weight and you arrive at the large amounts circulating online.
Two problems inside the conversion
- Body-weight scaling between mice and humans is an assumption rather than a rule.
- Fisetin absorbs poorly, so an equivalent milligram figure does not imply an equivalent tissue concentration.
Meanwhile the Interventions Testing Program, which retests promising compounds across independent sites, did not find a lifespan extension with fisetin.[6]
Show the numbers as a table
| When | Event | Detail |
|---|---|---|
| 2018 | D+Q in old mice | Function improved |
| 2018 | Fisetin screen | Top of 10 flavonoids |
| 2019 | First human pilot | 9 patients, 3 days |
| 2023 | ITP retest | No fisetin lifespan gain |
| 2024 | Clock pilot | 19 people, 6 months |
Can you tell if a senolytic worked?
Not outside a research setting, because senescent cell burden is measured by analyzing tissue. That is why the human trials took biopsies.
There are no completely sensitive and specific markers for senescent cells.
Without a marker there is no titration, no way to know when a repeat cycle is warranted, and no way to distinguish a working protocol from an inert one. Every schedule is a guess with a calendar attached.
Is a higher senolytic dose more effective?
Nobody knows, and the assumption is risky, because selectivity is the entire point of a senolytic: killing senescent cells while sparing healthy ones. That selectivity belongs to a specific concentration range, not to the molecule itself.
Pushing the dose up in pursuit of a stronger effect risks losing the selectivity that made the class interesting, and with poorly characterized compounds nobody knows where that line sits. Quercetin's own evidence summary describes limited bioavailability and modest effects at ordinary doses.[7]
What is a defensible position on senolytic dosage?
Treat the mouse concept as real, the human pilots as small tests of a prescription drug in 9 and 19 people, and the supplement protocols as extrapolations.
| Study | Compound | Who | Dosing | Result |
|---|---|---|---|---|
| Xu 2018 | Dasatinib plus quercetin | Aged mice | Intermittent | Function improved, remaining lifespan extended |
| Yousefzadeh 2018 | Fisetin | Progeroid and aged mice | Intermittent | Most potent of 10 flavonoids screened |
| Hickson 2019 | Dasatinib plus quercetin | 9 patients, kidney disease | 3 days | Fewer senescent cells in fat tissue |
| ITP 2023 | Fisetin | Mice, independent sites | Program protocol | No lifespan extension |
| Lee 2024 | Dasatinib plus quercetin | 19 people | 6 months | Older clocks read older; telomeres fell |
If you take flavonoid senolytics anyway, the honest framing is a bet on an unvalidated schedule, not the execution of a protocol, and a conversation with a clinician is the sensible first step. Our review of the senolytic evidence covers the class, and the fisetin page covers the compound with the most enthusiasm and the failed retest.
What would establish a real senolytic dosage?
Two trials that do not yet exist: a trial comparing doses against a measured reduction in senescent cell burden, followed by a trial showing that the reduction improves a clinical endpoint. Neither exists for any compound available without a prescription.
Until they do, confident numbers on this topic signal confidence rather than knowledge. Our supplement evidence review applies the same standard across the category.
Frequently asked questions
What is the standard senolytic dosage?
There is no standard. The human trials that exist used dasatinib with quercetin on intermittent schedules in tiny patient groups. Fisetin protocols circulating online are extrapolated from a mouse study, and no dose has been validated against a human outcome.
How long did the longest human senolytic pilot run?
Six months, in 19 people taking dasatinib with quercetin. Several older epigenetic clocks read older rather than younger and telomere length fell, while newer clocks showed no change. Duration did not buy a clear rejuvenation signal.
What is the hit-and-run protocol?
Two or three consecutive days of dosing, then weeks or months off, repeated monthly or quarterly in online protocols. The pattern comes from the animal literature and from the design of the small human pilots, and the specific intervals in circulation are conventions rather than findings.
How long after dosing did the first pilot look for senescent cells?
Eleven days after the last of 3 dosing days, using fat tissue biopsies from 9 patients with diabetic kidney disease. Nobody has shown how long that reduction lasts, which is the number any repeat schedule would need.
Did the stricter mouse program confirm fisetin's lifespan effect?
No. The Interventions Testing Program, which retests compounds across independent sites, found no lifespan extension with fisetin. The large intermittent doses online are scaled from the earlier single-lab mouse work that the retest did not back.
Why does quercetin's poor absorption matter for dosing?
Because the milligrams on a label do not translate into a tissue concentration. Quercetin's evidence summary describes limited bioavailability and modest effects at ordinary doses, so matching a trial's milligram figure does not mean matching what reached the cells.
Do the human senolytic trials involve fisetin at all?
No. Both human pilots cited here, 9 patients for 3 days (per Hickson 2019) and 19 people for 6 months (per Lee 2024), used dasatinib with quercetin. The fisetin schedules sold online have no human dosing trial behind them on this evidence, only mouse work.
Why can a blood test not guide a senolytic schedule?
Senescent cell burden is measured by analyzing tissue, and even researchers lack a completely sensitive and specific marker. Without one there is nothing to titrate against, so no test tells you when a repeat cycle is due.
Are senolytics safe at these doses?
The pilot trials reported acceptable short-term tolerability in patients. Dasatinib is a prescription drug with real toxicity. Fisetin and quercetin appear well tolerated at supplement doses, and the high intermittent amounts in protocols have not been studied for long-term safety in healthy people.
Should healthy people take senolytics at all?
Every human trial so far has enrolled patients with a disease, which is the appropriate place to test something new. Extending an unvalidated protocol to healthy people is exactly the leap the trials have not made.
Has any senolytic dose survived independent retesting?
Not in people, and no randomized replication exists. The one independent multi-site retest cited here, the Interventions Testing Program, tested fisetin in mice and found no lifespan extension. Neither human pilot had a comparison group, so no dose has yet been checked by a second team.
Is quercetin needed alongside fisetin?
No combination has been tested. The pairing people copy is dasatinib with quercetin, where the prescription drug is doing much of the work. Substituting fisetin for dasatinib produces a different protocol with no trial behind it.
What monitoring makes sense?
Nothing specific is established, since none of this is a validated therapy. Anyone taking a prescription senolytic is doing so under a clinician who will define monitoring. Anyone self-dosing flavonoids has no marker to follow.
What is the honest summary on senolytic dosage?
The class is one of the better ideas in aging biology and the dosing is entirely unsettled. Every protocol in circulation is a translation from mice or a copy of a tiny patient pilot, and the compound with the most enthusiasm behind it failed its lifespan retest.
References
7 sources, all link-checked; oldest check
- Fisetin is a senotherapeutic that extends health and lifespan. Yousefzadeh MJ et al. EBioMedicine 2018;36:18–28.Publisher blocks automated checks · last tried Sep 15, 2026
- Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002, dimethyl fumarate and mycophenolic acid do not. Harrison DE et al. GeroScience 2023 (NIA Interventions Testing Program; cited 64).The most rigorous multi-site mouse lifespan program tested fisetin and found no lifespan extension.Verified Sep 15, 2026
- Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin. Hickson LJ et al. EBioMedicine 2019;47:446–456.Small first-in-human senolytic trial.Publisher blocks automated checks · last tried Sep 15, 2026
- Senolytics improve physical function and increase lifespan in old age. Xu M et al. Nature Medicine 2018;24:1246–1256.Verified Sep 15, 2026
- Exploring the effects of dasatinib, quercetin and fisetin on DNA methylation clocks. Lee E et al. 2024 (cited 61).Assessed dasatinib plus quercetin senolytic treatment against DNA methylation, epigenetic age and immune cell subsets.Verified Sep 15, 2026
- Quercetin: evidence summary. Examine.com.Publisher blocks automated checks · last tried Sep 15, 2026
- Cellular senescence: defining a path forward. Gorgoulis V et al. Cell 2019 (cited 3,603).Consensus definition: a cell state triggered by stressful insults and certain physiological processes, with prolonged and generally irreversible cell-cycle arrest, secretory features, macromolecular damage and altered metabolism.Publisher blocks automated checks · last tried Sep 15, 2026
Every link above is re-requested on a schedule by an automated checker; the date shown is when it last answered. Publishers that block automated requests are marked as such rather than reported broken. Our editorial standards explain how a source gets cited here in the first place.
Filed by the Rapamycin.store evidence desk. Each source is re-checked when the page is reviewed.
Own a longevity or health brand?
Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.